CN1264522C - Medicinal composition, its preparation method and its use - Google Patents
Medicinal composition, its preparation method and its use Download PDFInfo
- Publication number
- CN1264522C CN1264522C CNB200410070499XA CN200410070499A CN1264522C CN 1264522 C CN1264522 C CN 1264522C CN B200410070499X A CNB200410070499X A CN B200410070499XA CN 200410070499 A CN200410070499 A CN 200410070499A CN 1264522 C CN1264522 C CN 1264522C
- Authority
- CN
- China
- Prior art keywords
- enzymolysis
- troxerutin
- brain
- preparation
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title abstract description 10
- 229960003232 troxerutin Drugs 0.000 claims abstract description 85
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 76
- 210000004556 brain Anatomy 0.000 claims abstract description 76
- 239000000284 extract Substances 0.000 claims abstract description 52
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 38
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 23
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 84
- 239000007924 injection Substances 0.000 claims description 69
- 238000002347 injection Methods 0.000 claims description 69
- 239000007788 liquid Substances 0.000 claims description 56
- 238000001914 filtration Methods 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 42
- 239000000706 filtrate Substances 0.000 claims description 37
- 239000000047 product Substances 0.000 claims description 33
- 239000006228 supernatant Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 102000035195 Peptidases Human genes 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 239000008215 water for injection Substances 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 15
- 238000000108 ultra-filtration Methods 0.000 claims description 14
- 238000005119 centrifugation Methods 0.000 claims description 12
- 230000002490 cerebral effect Effects 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 9
- 108090000631 Trypsin Proteins 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 239000012588 trypsin Substances 0.000 claims description 9
- 108090000284 Pepsin A Proteins 0.000 claims description 8
- 102000057297 Pepsin A Human genes 0.000 claims description 8
- 229940111202 pepsin Drugs 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000012805 post-processing Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 abstract description 9
- 230000008728 vascular permeability Effects 0.000 abstract description 7
- 230000001154 acute effect Effects 0.000 abstract description 6
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 5
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 206010019196 Head injury Diseases 0.000 abstract description 4
- 208000007536 Thrombosis Diseases 0.000 abstract description 4
- 210000005013 brain tissue Anatomy 0.000 abstract description 3
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 208000001297 phlebitis Diseases 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 60
- 230000000694 effects Effects 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 206010008118 cerebral infarction Diseases 0.000 description 10
- 239000012895 dilution Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000005262 decarbonization Methods 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 239000004365 Protease Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003708 ampul Substances 0.000 description 6
- 230000003925 brain function Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229940093181 glucose injection Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010008132 Cerebral thrombosis Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920001131 Pulp (paper) Polymers 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003195 fascia Anatomy 0.000 description 4
- -1 flavone compounds Chemical class 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 201000005060 thrombophlebitis Diseases 0.000 description 4
- IOYNGCZNYGEZRO-UHFFFAOYSA-N 3-ethyl-n,n,2-trimethyl-1h-indol-5-amine Chemical compound C1=C(N(C)C)C=C2C(CC)=C(C)NC2=C1 IOYNGCZNYGEZRO-UHFFFAOYSA-N 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 3
- 102400000967 Bradykinin Human genes 0.000 description 3
- 241000208278 Hyoscyamus Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000282894 Sus scrofa domesticus Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 206010034754 petechiae Diseases 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241001113926 Gelsemium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000012207 quantitative assay Methods 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QWMHJRQNEVHLGK-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrobromide Chemical compound Br.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O QWMHJRQNEVHLGK-BTVCFUMJSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000283026 Cervus elaphus Species 0.000 description 1
- 241000283007 Cervus nippon Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000009242 naomaitong Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002263 peptidergic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940074446 sodium potassium tartrate tetrahydrate Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a medicinal composition containing weinaolutong (7, 3', 4'-troxerutin) obtained by hydroxyethylating eldrin and brain extract which is extracted form brain tissue of mammalian except human. The medicinal composition contains 1 to 1000 parts of weinaolutong, by weight, and the weight of the weinaolutong in the medicinal composition is 0.1 to 200 times bigger than total nitrogen content in the brain extract. The invention also discloses preparation method and use of the medicinal composition. The medicinal composition can restrain platelet agglutination thereby preventing thrombosis, and can regulate and improve brain supersession, and is used for treating acute and chronic cerebrovascular disease and sequela such as brain dysfunctional caused by craniocerebral trauma and cerebrovascular disease; and can also be used for treating occlusive syndrome, arteriosclerosis, thrombosis phlebitis, capillary bleeding and dropsy caused by elevation of vascular permeability.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, Its Preparation Method And Use, specifically, relate to a kind of pharmaceutical composition, its preparation method and in the purposes of sequela medicines such as preparation treatment acute and chronic cerebrovascular disease and caused disordered brain function thereof by brain extract that extracts in the mammal cerebral tissue except that the people and troxerutin.
Background technology
Troxerutin (having another name called troxerutin) is rutin and the water-soluble flavone compounds that obtains semi-synthetic through hydroxyethylation, for with troxerutin (7,3 ', 4 '-troxerutin) being the mixture of master's hydroxyethyl rutin, the general medicinal anhydride of pressing calculates, and contains troxerutin (C
33H
42O
19) must not be less than 80.0% (injection) and 60.0% (pro ore).Troxerutin can suppress hematoblastic gathering, prevents thrombotic effect.The blood vessel injury that can cause medmain, Kallidin I simultaneously increases the resistance of blood capillary, reduces the permeability of blood capillary, can prevent the edema that vascular permeability raises and causes.
The clinical medical value of troxerutin has: be applicable to syndrome before hemiplegia that obliterated cerebral vascular disease causes, aphasia, the coronary heart disease infarction, central retinitis, thrombophlebitis, vascular permeability the raise edema, lymphedema, burn and the traumatic edema that cause, arteriosclerosis etc.
As one of component, constitute compound recipe with troxerutin, relevant patent also has open.Such as, application number 93107252.2 discloses a kind of compound henbane seed injection to artery or vein and preparation method thereof, and this injection of every 10ml contains hydrochloric acid mountain gelsemium henbane alkali 30-80mg, scopolamine hydrobromide 0.3-1.5mg, troxerutin 0.1-0.4g, glucose 200-400mg.Its preparation method is that to mix, bottle, seal, sterilize, inspect by random samples qualified back successively by the order of troxerutin-hydrochloric acid mountain gelsemium henbane alkali-scopolamine hydrobromide-glucose standby.
Application number 95109431.9 discloses a kind of compound recipe Naomaitong injection for cerebral angiopathy water formulation that is mixed, be characterized in: Radix Salviae Miltiorrhizae 100-300 part, troxerutin 5-15 part, citicoline 5-10 part, coenzyme A 1-2 part, 0.4 part of adenosine triphosphate, water 240-770 part, this medicine has the effect that suppresses erythrocyte and platelet aggregation, can prevent and treat thrombosis, can prevent and treat cerebral edema, promote neovascularity to generate, can prevent and treat senile dementia, can treat brain arteries and veins angiopathy.
Above-mentioned patent does not all relate to troxerutin and the assembly of animal brain extract, prepares new medicine.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition, this pharmaceutical composition is formed by brain extract that extracts in the mammal cerebral tissue except that the people and troxerutin assembly.
Another object of the present invention is to provide this preparation of drug combination method.
A further object of the present invention provides above-mentioned composition at preparation treatment acute and chronic cerebrovascular disease and by the purposes of sequela medicines such as cerebrovascular disease, the caused disordered brain function of cerebral trauma.
The invention still further relates to the purposes of pharmaceutical composition in the inaccessible syndrome of preparation treatment, arteriosclerosis, thrombophlebitis, capillary hemorrhage and vascular permeability raise the medicines such as edema that cause.
A kind of pharmaceutical composition of the present invention, wherein contain animal brain's extracting solution, contain a large amount of active polypeptide, several amino acids etc. in the brain tissue extract, the active polypeptide that contains, aminoacid are controlled when the ultrafiltration by the ultrafilter membrane of molecular cut off 5000-10000.
Pharmaceutical composition of the present invention, it is characterized in that containing the troxerutin (7 that rutin obtains through hydroxyethylation, 3 ', 4 '-troxerutin) with by the brain extract that extracts in the mammal cerebral tissue except that the people, containing troxerutin in the pharmaceutical composition is the 1-1000 weight portion, described weight portion can be the known content of field of medicaments such as μ g, mg, g, and wherein the weight ratio of total nitrogen content is 0.1～200 in troxerutin and the brain extract.
Wherein in the preferred pharmaceutical compositions in troxerutin and the brain extract weight ratio of total nitrogen content be 10-100; This weight ratio is 70-90 more preferably; Most preferably be 80.
Mammal cerebral tissue except that the people of the present invention is preferably the cerebral tissue of pig, Canis familiaris L., cattle, sheep, deer, horse or rabbit.
Consider the preferred pig brain tissue of above-mentioned mammal cerebral tissue from factors such as production cost, production technology, constant product quality, clinical efficacies.
Preparation of drug combination method of the present invention comprises that the preparation of brain extract and brain extract and troxerutin are mixed in proportion, and wherein the weight ratio of total nitrogen content is 0.1～200 in troxerutin and the brain extract, makes finished product preparation through post processing then.Wherein the preparation process of brain extract is: the animal brain of getting fresh and healthy, add the homogenate of 0.5-2.5 times of weight water for injection, be heated to 80-95 ℃, kept 15-30 minute, be cooled to hydrolysis temperature, be adjusted to the enzymolysis pH value, the proteolytic enzyme that adds brain weight 0.1-1.5%, carry out primary enzymolysis or secondary enzymolysis, primary enzymolysis liquid or secondary enzymolysis liquid, are handled through centrifugal filtration after 8-24 hour 4-8 ℃ of placement, and filtrate is the ultrafilter membrane ultrafiltration of 5000-10000 with molecular cut off, ultrafiltrate is a brain extract, and its total nitrogen content is 0.1～10mg/ml.
Described primary enzymolysis is behind the proteolytic enzyme that adds brain weight 0.1-1.5%, keeps 2-20 hour at this proteolytic enzyme hydrolysis temperature, keeps the enzymolysis pH value, is heated to 80-95 ℃ and kept 15-30 minute then, primary enzymolysis liquid.
Described proteolytic enzyme preferably uses trypsin, and it is 35-50 ℃ that enzymolysis is fit to temperature, and it is 7.5-8.5 that enzymolysis is fit to pH value, and the enzymolysis pH value is preferably 7.8～8.2, and hydrolysis temperature is preferably 37～42 ℃; For keeping temperature stabilization, can take the method for interlayer water bath heat preservation.
Described secondary enzymolysis process is adjusted to the enzymolysis pH value for primary enzymolysis liquid is cooled to hydrolysis temperature, adds the proteolytic enzyme of brain weight 0.1-1.5%, enzymolysis 2-20 hour, keep the enzymolysis pH value, be heated to 80-95 ℃ then and kept 15-30 minute, get secondary enzymolysis liquid.
Described proteolytic enzyme preferably uses pepsin, and hydrolysis temperature is 35-50 ℃, and hydrolysis temperature is preferably 37～42 ℃, and the enzymolysis pH value is 2.5-3.5, and the enzymolysis pH value is preferably 2.5-3.2.
Described hydrolysis temperature is the operating temperature of biologically active of the protease correspondence of above-mentioned use, and under this temperature, the protease of use has normal biological activity.
Described enzymolysis pH value is the environment pH value that is fit to employed protease, and under this pH value, the protease of use has normal biological activity.
Centrifugal filtration after the described primary enzymolysis is treated to: centrifugal back separation of supernatant, and with supernatant liquid filtering, the filtrate adjust pH is 3.5-4.5, be heated to 80-95 ℃, kept 15-30 minute, placed 8-24 hour at 4-8 ℃, centrifugal back separation of supernatant, with supernatant liquid filtering, the filtrate adjust pH is 6.5-7.5, is heated to 80-95 ℃, kept 15-30 minute, placed 8-24 hour at 4-8 ℃, centrifugal then, supernatant gets filtrate after filtration.
Centrifugal filtration after the described secondary enzymolysis is treated to: centrifugal back separation of supernatant, and with supernatant liquid filtering, the filtrate adjust pH is 8.0-10.0, be heated to 80-95 ℃, kept 15-30 minute, placed 8-24 hour at 4-8 ℃, centrifugal back separation of supernatant, with supernatant liquid filtering, the filtrate adjust pH is 6.5-7.5, is heated to 80-95 ℃, kept 15-30 minute, placed 8-24 hour at 4-8 ℃, centrifugal then, supernatant gets filtrate after filtration.
Described centrifugal condition is 4000 rev/mins, and centrifugation time is 15-30 minute.
Describedly be filtered into paper pulp filtering general in the prior art or the clarification plate filters.
The said process adjust pH uses hydrochloric acid and/or sodium hydroxide.
Described proteolytic enzyme is the proteolytic enzyme that uses in the prior aries such as trypsin, pepsin, papain, bromelain, neutral protease, and occupation mode can be single use, also can be successively to use different enzymes; Preferred trypsin or the pepsin of using.The pepsin regular size is 1: 3000-10000, trypsin regular size are 1: 250, and for making production technology of the present invention, constant product quality, the enzyme of use should be as far as possible provided by fixing manufacturer.
Above-mentioned ultrafilter membrane is preferably the ultrafilter membrane that molecular cut off is 6000-10000, and more preferably molecular cut off is 8000 ultrafilter membrane.The ultrafilter membrane that uses is the commercially available prod, and its manufacturer should be the production unit of industry approval, and the filter membrane model of use and size can be determined according to concrete volume of production, the ultrafilter size selected for use.
The dosage form of above-mentioned finished product preparation is an acceptable forms on the pharmaceutics, such as tablet, capsule, granule, oral liquid, small-volume injection, bulk capacity injection or lyophilized injectable powder etc., be preferably small-volume injection, bulk capacity injection or lyophilized injectable powder, most preferably be small-volume injection.Therefore, described post processing can be to carry out according to the conventional method of acceptable forms on the preparation pharmaceutics.
Brain extract after the secondary enzymolysis of the present invention contains polypeptide and free amino acid, meets national drug standards Cerebrolysin Vial quality standard.The every gram of Cerebrolysin Vial (for oral use) contains total nitrogen and should be 80-100mg behind the brain extract concentrate drying after the secondary enzymolysis of the present invention, meets Cerebrolysin Vial (for oral use) national drug standards; Brain extract after the secondary enzymolysis of the present invention (injection, aqueous solution) dilution or concentrate after can be used for preparing brain protein hydrolysate injection, and meet the national drug standards.Cerebrolysin Vial is the peculiar peptidergic nerve nutrient of a kind of brain; can act on nervus centralis in many ways, regulate and improve neuronic metabolism, promote the formation of synapse; induce neuronic differentiation, and further neuroprotective cell is avoided the infringement of various ischemias and neurotoxin.Can pass through blood brain barrier, promote the synthetic of brain internal protein, influence respiratory chain, have the protective capability of anti-hypoxia, improve the metabolism of brain self-energy, but other hormone systems of activated adenyl cyclase and catalysis provide neurotransmitter, peptide hormone and coenzyme precursors.Can be used for craniocerebral trauma, apoplexy sequela is concentrated the doing well,improving of obstacle with hypomnesis and attention.Brain insufficiency there is the auxiliary improvement effect, also is used for potein deficiency, patient neurasthenia and the case of general protein digestibility malabsorption.
Pharmaceutical composition of the present invention can be applicable to prepare the purposes of acute and chronic cerebrovascular disease medicament aspects such as treatment cerebral thrombosis, cerebral embolism, brain spasm, can be used for treating craniocerebral trauma and cerebrovascular disease (incomplete brain blood supply, cerebral infarction) and cause sequela such as disordered brain function, and as raise the application in the medicines such as edema that cause of treatment inaccessible syndrome, arteriosclerosis, thrombophlebitis, capillary hemorrhage and vascular permeability.
Research worker of the present invention is tested discovery in a large number, and when troxerutin weight in this pharmaceutical composition is in the brain extract during 80 times of total nitrogen content, the synergism of the two is best, is more conducive to absorption by human body and utilization.
The present invention most preferably specification of medicine composition injection is:
2ml:80mg (troxerutin): 1mg (total nitrogen);
5ml:200mg (troxerutin): 2.5mg (total nitrogen);
10ml:400mg (troxerutin): 5mg (total nitrogen);
Intramuscular injection: a 2～4ml, 2 times on the one
Intravenous drip: a 10ml, once-a-day, use with 250～500ml normal saline or 5% glucose injection dilution back.20 is a course of treatment, available 1～3 course of treatment, 3～7 days at interval per course of treatment.
Pharmaceutical composition of the present invention contains the active substance of the disordered brain function sequela for the treatment of cerebrovascular disease and causing, this active matter mass-energy is regulated and is improved the brain metabolism, adopt the synergism of troxerutin and brain extract active substance, reached best clinical effectiveness.
This pharmaceutical composition has been brought into play the synergism of the two by the organic assembling of brain extract and troxerutin, is more conducive to effective treatment of cerebrovascular disease and the improvement of the sequela that caused by cerebrovascular disease.
Pharmaceutical composition of the present invention contains the active substance of the disordered brain function sequela for the treatment of cerebrovascular disease and causing, comprises a large amount of active polypeptide and the several amino acids that contain in troxerutin, the brain extract.Troxerutin can suppress hematoblastic gathering, prevents thrombotic effect.The blood vessel injury that can cause medmain, Kallidin I simultaneously increases the resistance of blood capillary, reduces the permeability of blood capillary, can prevent the edema that vascular permeability raises and causes.The contained a large amount of active polypeptide of brain extract, several amino acids etc. can see through blood brain barrier; act on nervus centralis in a variety of forms; adjust and improve the neuron metabolism; and influence its respiratory chain; have activation, improve the activity of neurotransmitter and enzyme in the brain, the neuroprotective cell is avoided the infringement of various ischemias and neurotoxin.Can increase the utilization of cerebral tissue, improve the brain cell anaerobic condition, to the protective effect of anoxybiotic cerebral tissue tool glucose.Can be applicable to prepare the purposes of acute and chronic cerebrovascular disease medicament aspects such as treatment cerebral thrombosis, cerebral embolism, brain spasm, can be used for treating craniocerebral trauma and cerebrovascular disease (incomplete brain blood supply, cerebral infarction) and cause sequela such as disordered brain function, and as raise the application in the medicines such as edema that cause of treatment inaccessible syndrome, arteriosclerosis, thrombophlebitis, capillary hemorrhage and vascular permeability.
Description of drawings
Fig. 1 is treatment group and the comparison of matched group clinical efficacy in the comparative example 3
Fig. 2 is treatment group and matched group neurologic impairment integration (X ± S) relatively in the comparative example 3
The specific embodiment
Embodiment 1
Get fresh and healthy Medulla sus domestica 10kg, remove impurity such as fascia, wash with water for injection, add 10L water for injection, homogenate is heated 80 ℃, kept 15 minutes, and be cooled to 42 ℃, regulate pH value 7.5, add 45g trypsin U.S. DIFCO company, specification: 500g) 42 ℃ of enzymolysis 3 hours, control pH value 8.5 in the enzymolysis process, take out, be heated to 80 ℃, kept 20 minutes, get primary enzymolysis liquid;
4 ℃ of placements are centrifugal after 24 hours, and centrifugal condition is 4000 rev/mins, and centrifugation time is 15 minutes, paper pulp filtering, supernatant adjust pH 3.5 heats 95 ℃, kept 20 minutes, 4 ℃ of placements are centrifugal after 12 hours, and centrifugal condition is 4000 rev/mins, centrifugation time is 20 minutes, paper pulp filtering, filtrate adjust pH 6.5, be heated to 90 ℃, kept 15 minutes, place after 8 hours centrifugal for 8 ℃, centrifugal condition is 4000 commentaries on classics parts, and centrifugation time is 20 minutes, gets filtrate; Filtrate is 6000 ultrafilter membrane (U.S. millipore company, standard ultrafiltration system) ultrafiltration with molecular cut off, and ultrafiltrate is brain extract, and wherein total nitrogen content is 4mg/ml.
Take by weighing the pure product 80g of injection troxerutin, can be made into the 2000ml medicinal liquid, finally make 1000 of little molten amount injections (specification is 2ml:80mg troxerutin and 1mg total nitrogen) with the 250ml brain extract.The water for injection of getting dosing amount about 40% is in dense preparing tank, add troxerutin and be stirred well to dissolving fully, the activity that adds total dose volume 0.05% stirs boiled 15 minutes, and fluid temperature is reduced to 40～50 ℃, with the medicinal liquid decarbonization filtering to dilute preparing tank, in dilute preparing tank, drop into brain extract, add water to the dosing amount, regulate pH value 6.8～7.0, medicinal liquid after filtration behind the system filtration embedding in the 2ml ampoule, sterilization promptly gets small-volume injection.
Embodiment 2
Get fresh and healthy Medulla sus domestica 10kg, remove impurity such as fascia, wash with water for injection, add 10L water for injection, pH value 8.2 is regulated in homogenate, heat 80 ℃, kept 15 minutes, be cooled to 42 ℃, add 80g trypsin U.S. DIFCO company, specification: 500g) 42 ℃ of enzymolysis 10 hours, control pH value 8.2 in the enzymolysis process, take out, be heated to 80 ℃, kept 20 minutes, get primary enzymolysis liquid;
Primary enzymolysis liquid is cooled to 44 ℃, and regulating pH value is 2.5, adds 50g pepsin (the grand chemical reagent company limited that reaches of Xiamen star; 1: 10000; Specification: 100g), enzymolysis 10 hours, process pH value is controlled to be 2.5, is heated to 90 ℃ then and keeps 20 minutes, obtains secondary enzymolysis liquid;
With 4000 rev/mins speed centrifugal 30 minutes, supernatant to be clarified plate filter, the filtrate adjust pH is for g.0, be heated to 95 ℃, kept 15 minutes, and placed 20 hours at 6 ℃, identical centrifugation is separated supernatant, filter, the filtrate adjust pH is 7.3, is heated to 85 ℃, keeps 25 minutes, placed 15 hours at 6 ℃ then, same way as is centrifugal, filter to get filtrate; Filtrate is 10000 ultrafilter membrane (U.S. millipore company, standard ultrafiltration system) ultrafiltration with molecular cut off, and ultrafiltrate is brain extract, and wherein total nitrogen content is 6mg/ml.
Take by weighing the pure product 60g of injection troxerutin, can be made into the 2000ml medicinal liquid, finally make 1000 of little molten amount injections (specification is 2ml:60g troxerutin and 1.5mg total nitrogen) with the 250ml brain extract.The water for injection of getting dosing amount about 40% is in dense preparing tank, add troxerutin and be stirred well to dissolving fully, the activity that adds total dose volume 0.05% stirs boiled 15 minutes, and fluid temperature is reduced to 40～50 ℃, with the medicinal liquid decarbonization filtering to dilute preparing tank, in dilute preparing tank, drop into brain extract, add water to the dosing amount, regulate pH value 7.1～7.3, medicinal liquid after filtration behind the system filtration embedding in the 2ml ampoule, sterilization promptly gets small-volume injection.
Embodiment 3
Get fresh and healthy Medulla Bovis seu Bubali 10kg, remove impurity such as fascia, wash with water for injection, add 25L water for injection, pH value 9.0 is regulated in homogenate, heat 95 ℃, kept 30 minutes, be cooled to 38 ℃, add the 150g trypsin, be incubated 4 hours, control pH value 8.0 is heated to 85 ℃ then in the enzymolysis process, kept 30 minutes, and got primary enzymolysis liquid;
Placed 8 hours for 8 ℃, centrifugal, centrifugal condition is 4000 rev/mins, and centrifugation time is 20 minutes, the supernatant paper pulp filtering, filtrate adjust pH 4.0 heats 80 ℃, keeps 30 minutes, placed 12 hours for 5 ℃, centrifugal, centrifugal condition is 4000 rev/mins, and centrifugation time is 30 minutes, supernatant liquid filtering, filtrate adjust pH 7.0 is heated to 95 ℃, kept 30 minutes, 7 ℃ of placements are centrifugal after 18 hours, and centrifugal condition is 4000 rev/mins, centrifugation time is 30 minutes, and supernatant liquid filtering gets filtrate; Filtrate is 8000 ultrafilter membrane ultrafiltration with molecular cut off, and ultrafiltrate is brain extract, and its total nitrogen content is 1.4mg/mL.
Take by weighing the pure product 100g of injection troxerutin, can be made into the 2000ml medicinal liquid, finally make 1000 of little molten amount injections (specification is 2ml:100mg troxerutin and 0.7mg total nitrogen) with the 500ml brain extract.The water for injection of getting dosing amount about 40% is in dense preparing tank, add troxerutin and be stirred well to dissolving fully, the activity that adds total dose volume 0.05% stirs boiled 15 minutes, and fluid temperature is reduced to 40～50 ℃, with the medicinal liquid decarbonization filtering to dilute preparing tank, in dilute preparing tank, drop into brain extract, add water to the dosing amount, regulate pH value 7.0～7.2, medicinal liquid after filtration behind the system filtration embedding in the 2ml ampoule, sterilization promptly gets small-volume injection.
Embodiment 4
According to the operation of embodiment 3, obtain primary enzymolysis liquid.
Primary enzymolysis liquid is cooled to 45 ℃, and regulating pH value is 3.5, adds 100g pepsin (the grand chemical reagent company limited that reaches of Xiamen star; 1: 10000; Specification: 100g), enzymolysis 2 hours, process pH value is controlled to be 3.2, is heated to 95 ℃ then and keeps 15 minutes, obtains secondary enzymolysis liquid;
With centrifugal 30 minutes of 4000 speed of changeing part, supernatant to be clarified plate filter, the filtrate adjust pH is 10.0, be heated to 80 ℃, kept 30 minutes, and placed 8 hours at 4 ℃, identical centrifugation is separated supernatant, filter, the filtrate adjust pH is 7.0, is heated to 90 ℃, keeps 30 minutes, placed 15 hours at 6 ℃ then, same way as is centrifugal, filter to get filtrate; Filtrate is 8000 ultrafilter membrane (U.S. millipore company, standard ultrafiltration system) ultrafiltration with molecular cut off, and ultrafiltrate is brain extract, and wherein total nitrogen content is 2.5mg/ml.
Operation according to embodiment 3 makes injection.
Get fresh and healthy brain of Cervus nippon Temminck (C. elaphus L.) 10kg, remove impurity such as fascia, with the water for injection washing, add 5L water for injection, pH value to 8.5 is regulated in homogenate, heats 85 ℃, keeps 20 minutes, is cooled to 45 ℃, adds 40g pepsin (the grand chemical reagent company limited that reaches of Xiamen star; 1:10000; Specification: 100g), 45 ℃ of enzymolysis 20 hours, control pH value 2.5 was heated to 95 ℃ then in the enzymolysis process, keeps 15 minutes, obtains primary enzymolysis liquid;
Place after 10 hours centrifugal for 7 ℃, centrifugal condition is 4000 rev/mins, centrifugation time is 30 minutes, and supernatant clarification plate filters filtrate adjust pH 3.5, be heated to 80 ℃, kept 30 minutes, 8 ℃ of placements are centrifugal after 8 hours, centrifugal, the filtration of same way as, filtrate adjust pH 7.3, be heated to 85 ℃, kept 15 minutes, place after 24 hours for 4 ℃, centrifugal, the filtration of same way as, get filtrate, filtrate is 8000 ultrafilter membrane (U.S. millipore company, standard ultrafiltration system) ultrafiltration with molecular cut off, ultrafiltrate is brain extract, and wherein total nitrogen content is 7mg/ml.
Take by weighing the pure product 100g of injection troxerutin, can be made into the 2000ml medicinal liquid, finally make 1000 of little molten amount injections (specification is 2ml:100mg troxerutin and 3.5mg total nitrogen) with the 500ml brain extract.The water for injection of getting dosing amount about 40% is in dense preparing tank, add troxerutin and be stirred well to dissolving fully, the activity that adds total dose volume 0.05% stirs boiled 15 minutes, and fluid temperature is reduced to 40～50 ℃, with the medicinal liquid decarbonization filtering to dilute preparing tank, in dilute preparing tank, drop into brain extract, add water to the dosing amount, regulate pH value 7.0～7.2, medicinal liquid after filtration behind the system filtration embedding in the 2ml ampoule, sterilization promptly gets small-volume injection.
Embodiment 6
According to the operation of embodiment 5, obtain primary enzymolysis liquid.
Primary enzymolysis liquid is cooled to 50 ℃, and regulating pH value is 7.8, adds 80g trypsin U.S. DIFCO company, specification: 500g), enzymolysis 10 hours, process pH value is controlled to be 7.8, is heated to 90 ℃ then and keeps 20 minutes, obtains secondary enzymolysis liquid;
With centrifugal 30 minutes of 4000 speed of changeing part, supernatant to be clarified plate filter, the filtrate adjust pH is 9.0, be heated to 85 ℃, kept 25 minutes, and placed 10 hours at 8 ℃, identical centrifugation is separated supernatant, filter, the filtrate adjust pH is 7.2, is heated to 80 ℃, keeps 20 minutes, placed 25 hours at 6 ℃ then, same way as is centrifugal, filter to get filtrate; Filtrate is 6000 ultrafilter membrane (U.S. millipore company, standard ultrafiltration system) ultrafiltration with molecular cut off, and ultrafiltrate is brain extract, and wherein total nitrogen content is 8.0mg/ml.
Operation according to embodiment 5 makes injection.
Get fresh and healthy Medulla sus domestica 10kg, add the homogenate of 15I water for injection, standby with reference to embodiment 1 preparation brain extract, wherein total nitrogen content is 2.4mg/ml.
Take by weighing the pure product 80g of injection troxerutin, can be made into the 2000ml medicinal liquid, finally make 400 of little molten amount injections (specification is 5ml:200mg troxerutin and 1.5mg total nitrogen) with the 250ml brain extract.The water for injection of getting dosing amount about 40% is in dense preparing tank, add troxerutin and be stirred well to dissolving fully, the activity that adds total dose volume 0.05% stirs boiled 15 minutes, and fluid temperature is reduced to 40～50 ℃, with the medicinal liquid decarbonization filtering to dilute preparing tank, in dilute preparing tank, drop into brain extract, add water to the dosing amount, regulate pH value 6.8～7.0, medicinal liquid after filtration behind the system filtration embedding in the 2ml ampoule, sterilization promptly gets small-volume injection.
Embodiment 8
According to the operation among the embodiment 1, the preparation brain extract.
Take by weighing the pure product 80g of injection troxerutin, can be made into the 2000ml medicinal liquid, finally make 200 of little molten amount injections (specification is 10ml:400mg troxerutin and 20mg total nitrogen) with the 1000ml brain extract.The water for injection of getting dosing amount about 30% is in dense preparing tank, add troxerutin and be stirred well to dissolving fully, the activity that adds total dose volume 0.05% stirs boiled 15 minutes, and fluid temperature is reduced to 40～50 ℃, with the medicinal liquid decarbonization filtering to dilute preparing tank, in dilute preparing tank, drop into brain extract, add water to the dosing amount, regulate pH value 6.8～7.0, medicinal liquid after filtration behind the system filtration embedding in the 2ml ampoule, sterilization promptly gets small-volume injection.
Embodiment 9～14
With reference to embodiment 1～6, brain extract and troxerutin carry out proportioning, by known method, make granule, and dry back tabletting gets tablet.
With reference to embodiment 1～5, brain extract and troxerutin carry out proportioning, add suitable excipient (as Dextran 40, mannitol etc.), carry out the degerming fill, and by known method, the freeze-dried powder product is made in lyophilization.
Embodiment 21～26
With reference to embodiment 1～5, brain extract is put in the dilute preparing tank; In dense preparing tank, drop into the sodium chloride of troxerutin and 0.85% final preparation cumulative volume, add 0.4 ‰ active carbons and boil decarbonization filtering, after the cooling, with medical filtration to dilute preparing tank, add water for injection to the dosing amount in dilute preparing tank, transferring PH is 6.8～7.0, filters.Embedding is in infusion bottle, and 100 ℃ of flowing steam sterilizations 45 minutes promptly get infusion products.
Experimental example 1
This experimental example is the most preferably detection of the injection inspection item of pharmaceutical composition small-volume injection (every ml contains 40mg troxerutin and 0.5g total nitrogen) appearance character, pH value, protein, pyrogen, undue toxicity and other regulation of the present invention.
√ this product is yellow or sundown clear liquid.
√ measures according to two appendix VI of Chinese Pharmacopoeia version in 2000 H, and this product pH value should be 5.5-7.5.
√ gets this product 2ml, adds 20% sulfosalicylic acid solution 2ml, and solution should be clarified.
√ pyrogen test: get this product, be diluted to the solution that contains troxerutin 20mg among every ml, check (two appendix XI of Chinese Pharmacopoeia version in 2000 D) in accordance with the law with sodium chloride injection.Dosage should be up to specification by the every kg injection of rabbit body weight this product 2ml.
The √ undue toxicity measures: get this product, be diluted to the solution that contains troxerutin 20mg among every ml with sodium chloride injection, check (two appendix XIC of Chinese Pharmacopoeia version in 2000) in accordance with the law.Press intravenous administration, should be up to specification.
√ other: should meet under the injection item relevant every regulation (2000 editions two appendix I B of Chinese Pharmacopoeia).
Experimental example 2
This experimental example is the most preferably qualitative determination of the middle key component of pharmaceutical composition small-volume injection (every ml contains 40mg troxerutin and 0.5mg total nitrogen) of the present invention.
√ gets this product 0.5ml, and thin up is to 20ml, and it is a small amount of to add hydrochloric acid 1ml and zinc powder, puts in the water-bath and heats, and shows the redness that continues.
√ gets this product 0.5ml, and thin up is to 20ml, and it is a small amount of to add aluminum chloride, and solution shows glassy yellow.
√ gets this product 2ml, adds ninhydrin solution number droplet, and heating should show bluish violet.
In the chromatogram that √ writes down under troxerutin assay item, the main peak retention time of need testing solution should be consistent with the retention time at troxerutin reference substance peak.
More than three kinds of experiments be the qualitative reactions of the contained component of pharmaceutical composition of the present invention, illustrate and contain definite component in the drug regimen of the present invention.
Experimental example 3
This experimental example is the most preferably troxerutin quantitative assay in the pharmaceutical composition small-volume injection (every ml contains 40mg troxerutin and 0.5mg total nitrogen) of the present invention.
This experimental example is measured by high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2000).
√ chromatographic condition and system suitability test; With octadecylsilane chemically bonded silica is filler; With 0.1% citric acid soln-second eyeball-oxolane (85: 9: 6) is mobile phase: the detection wavelength is 254nm.Number of theoretical plate calculates by the troxerutin peak should be not less than 2000.Troxerutin peak and the peak-to-peak separating degree of other materials should meet the requirements.
The √ algoscopy: it is an amount of to get this product, quantitatively is diluted to the solution that contains troxerutin 0.20mg among every 1ml with mobile phase, as need testing solution, gets 10 μ l and injects chromatograph of liquid, the record chromatogram; It is an amount of that precision takes by weighing the troxerutin reference substance in addition, makes the solution that contains troxerutin 0.20mg among every 1ml with mobile phase dissolving and dilution, and product solution is measured with method in contrast, presses external standard method with calculated by peak area.
√ troxerutin content should be 90～110% of labelled amount.
√ the results are shown in following table by three batches of mensuration:
| Lot number | Account for labelled amount % |
| 20020603 | 103.7 |
| 20020604 | 104.7 |
| 20020605 | 100.6 |
Experimental example 4
This experimental example is the most preferably quantitative assay of the middle total nitrogen of pharmaceutical composition small-volume injection (every ml contains 40mg troxerutin and 0.5mg total nitrogen) of the present invention.
Get this product and measure (two appendix VII of Chinese Pharmacopoeia version in 2000 D) in accordance with the law.
By the result of three batches of mensuration, total nitrogen content should be 85～115% of labelled amount in this product, sees table:
| Lot number | Account for labelled amount % |
| 20020603 | 92.3 |
| 20020604 | 99.6 |
| 20020605 | 104.6 |
Experimental example 5
This experimental example detects for the main project that embodiment 2 prepared brain extracts are undertaken by the brain protein hydrolysate injection standard.
The √ amino acid content is measured: get this product, carry out separation determination with suitable amino-acid analyzer or high performance liquid chromatograph; Other gets the reference substance solution of the respective concentration that corresponding aminoacid reference substance makes, and measures with method.Press external standard method with each amino acid whose content of calculated by peak area.
Measurement result is as follows:
It is 34.70mg/ml that every 1ml contains free amino acid, wherein:
Aspartic Acid 3.05mg/ml glutamic acid 3.89mg/ml serine 0.25mg/ml
Histidine 1.22mg/ml glycine 1.49mg/ml threonine 0.24mg/ml
Alanine 2.99mg/ml arginine 0.55mg/ml valine 1.94mg/ml
Methionine 0.43mg/ml isoleucine 1.90mg/ml phenylalanine 1.80mg/ml
Leucine 6.18mg/ml lysine 6.55mg/ml proline 2.22mg/ml
The √ total nitrogen content is measured: get this product, measure (two appendix VII of Chinese Pharmacopoeia version in 2000 D) in accordance with the law, total nitrogen is 6.10mg/ml.
√ differentiates (1): get this product 2ml, add two gland reagent that contract (get copper sulfate 0.75g and sodium potassium tartrate tetrahydrate 0.3g, add water 250ml and make dissolving,
Under agitation add 10% sodium hydroxide solution 150ml, add water to 500ml) 4ml, displaing amaranth, up to specification.
√ differentiates (2): get this product, according to high performance liquid chromatography (two appendix V of Chinese Pharmacopoeia version in 2000 D) test.
Chromatographic condition: use gel chromatographic columns: with phosphate buffer (get dipotassium hydrogen phosphate 10.63g and potassium dihydrogen phosphate 5.31g, add isopropyl alcohol 50ml, add water to 1000ml, with phosphoric acid regulating ph value to 7.0) is mobile phase; Flow velocity is per minute 1ml.
Algoscopy: get each 10 υ l of contrast solution and need testing solution and inject chromatograph of liquid, the record chromatogram, the chromatogram of need testing solution should with the chromatogram basically identical of contrast solution, up to specification.
The √ index of refraction: the index of refraction of this product (two appendix VI of Chinese Pharmacopoeia version in 2000 H) is 1.342, and is up to specification.
PH value: pH value is 7.2 (two appendix VI of Chinese Pharmacopoeia version in 2000 H), and is up to specification.
√ protein: get this product 5ml, add 20% sulfosalicylic acid 2ml, solution should be clarified, and is up to specification.
Comparative example 1
This example is most preferably a pharmaceutical composition small-volume injection (every ml contains 40mg troxerutin and 0.5mg total nitrogen) and the clinical comparison of troxerutin injection at the treatment cerebral thrombosis of the present invention, the good efficacy of injection of the present invention is described, promptly the coordinating effect of troxerutin and brain extract is better than using separately troxerutin injection.
Clinical settings:
The cerebral thrombus patient is divided into 2 groups at random.
58 examples are organized in treatment, and wherein the male is 48 examples, and the women is 10 examples.Age 41-79 year, average 61.3 years old.
Matched group 51 examples, wherein the male is 42 examples, the women is 9 examples.Age 43-82 year, average 60.5 years old.All cases are the first patient of cerebral thrombosis, meet the academic diagnostic criteria that can work out of cerebrovascular, all do not see intracranial hemorrhage through CT scan.
Therapeutic Method:
The equal intravenous drip troxerutin injection of treatment group patient, a 400mg, 1 time on the one: instil with 5～10% glucose injections or low molecular dextran injection dilution back, 20 is a course of treatment, treats 3 courses of treatment, as the treatment group.
Matched group patient intravenous drip injection of the present invention, a 10ml once-a-day, uses with 250～500ml normal saline or 5% glucose injection dilution back.20 is a course of treatment, treats 3 courses of treatment, in contrast group.
Efficacy determination:
√ cures: transference cure, and language is fluent, and the energy independent ambulation is taken care of oneself, and the affected limb Myodynamia recovery is to more than the IV level;
√ takes a turn for the better; Main physical signs is obviously recovered, and symptom has improvement in various degree, more than the affected limb Myodynamia recovery II level;
√ is invalid: symptom, sign no change or sb.'s illness took a turn for the worse.
Therapeutic outcome:
The total effective rate and the curative effect of treatment group and matched group are compared, be significant difference, the results are shown in following table.
Treatment group and matched group curative effect are relatively
| Matched group (n=58) | Treatment group (n=58) | |||
| It is invalid effectively total to cure improvement | Example several 7 49 2 56 | (％) (12.1) (84.5) (3.4) (96.6) | Example several 3 39 9 42 | (％) (5.9) (76.5) (17.6) (82.4) |
Annotate: two groups of curative effects compare p＜0.01
Comparative example 2
This example is most preferably a pharmaceutical composition small-volume injection (every ml contains 40mg troxerutin and 0.5mg total nitrogen) and the clinical comparison of troxerutin injection at the treatment cerebral infarction of the present invention, illustrate that injection of the present invention has good efficacy, curative effect is better than the multiple plain injection of brain.
Clinical settings:
33 routine cases are divided into 2 groups according to the medication difference:
The multiple plain injection group of √ brain: male's 12 examples, women's 5 examples:
Of the present invention group of √: male's 11 examples, women's 5 examples.
Therapeutic Method:
√ uses injection group of the present invention: intravenous drip, and a 10ml, once-a-day, with instiling at a slow speed in 250ml normal saline or the 5% glucose injection dilution back.Treat 2 courses of treatment.
√ makes the multiple plain injection group of requiring mental skill: intravenous drip, and a 10ml-20ml, 1 time on the one, with instiling at a slow speed in 250ml normal saline or the 5% glucose injection dilution back.Treat 2 courses of treatment.
Efficacy determination:
Judge that curative effect is as the criterion to leave hospital, be in hospital 15 days with interior person's 3 examples; 16-30 days person's 30 examples.
√ cures: symptom and sign complete obiteration, take care of oneself, as usual work.
√ cures substantially: the paralysis human body, and Myodynamia recovery is left over part pathology sign to the 4-5 level, and life is taken care of oneself substantially.
√ takes a turn for the better: symptom and sign improves, and muscular strength improves the 1-2 level, and language function partly recovers, and life can not be taken care of oneself fully.
√ is invalid or dead: the sings and symptoms no change, or increase the weight of to death.
The √ responding time: cardinal symptom begins to take a turn for the better, and is the shortest 1 day, the longest 28 days, general 7-14 days.
The result compares:
Two groups of curative effects compare (example)
| The medication group | Significant figure | Cure | The basic healing | Take a turn for the better | No change | Sum | Effective percentage % |
| The multiple plain group of | 15 | 3 | 4 | 8 | 2 | 17 | 88.2％ |
| Of the present invention group | 16 | 3 | 12 | 1 | 0 | 16 | 100％ |
Comparative example 3
This example is most preferably pharmaceutical composition small-volume injection (every ml contains 40mg troxerutin and 0.5mg total nitrogen) and the clinical comparison of troxerutin injection aspect the treatment cerebral infarction of the present invention, the good efficacy of injection of the present invention is described, promptly the coordinating effect of troxerutin and brain extract is better than using separately troxerutin injection.
Clinical settings:
Patients with Cerebral Infarction totally 120 examples is divided into two groups at random.120 examples are falls ill 72 hours with interior internal carotid artery system Patients with Cerebral Infarction, meets the diagnostic criteria of the 4th the cerebrovascular academic conference in the whole nation, and makes a definite diagnosis through cranium brain CT or MR1 inspection.120 examples are divided into two groups at random, injection for treating group 60 examples of the present invention, troxerutin injection matched group 60 examples.Two groups of ages, sex, courses of disease, fall ill, comparability is arranged to administration time, history of past illness, complication there was no significant difference.
Therapeutic Method:
Two groups of patients all take the circumstances into consideration to use dehydrant and other symptomatic treatments, but all without medicines such as other blood vessel dilating, anticoagulants.Injection for treating group of the present invention, one time 10ml adds, and instils with 250ml normal saline dilution back every day 1 time, and 14 days is a course of treatment.The troxerutin injection matched group, a 400mg, every day 1 time, quiet of glucose injection with 5%～10% or low molecular dextran injection dilution back, 14 days is a course of treatment.
Efficacy determination:
Observe the variation of two groups of patient function of nervous system, blood flow index before and after the treatment.Efficacy assessment standard is the marked improvement that is almost recovered, 5 grades of progress, no change, deterioration, and the result adopts statistical procedures, and measurement data adopts μ check and X
2Check.
Therapeutic outcome:
Curative effect has significant difference (P＜0.01) between treatment group and the matched group, sees Fig. 1; The neurologic impairment integration relatively before and after the treatment, compare no significant difference (P＜0.005) before and after the treatment between two groups, treatment back treatment group neurologic impairment obviously alleviates (P＜0.01) than matched group, sees Fig. 2: do not find apparent side effect during whole blood viscosity reaches before and after two groups of treatments.
Interpretation of result:
Injection of the present invention can combine with the adenosine carrier protein on the platelet membrane; the content of cycli phosphate glycosides (cAMP) in the platelet increasing; thereby suppress erythrocyte and platelet aggregation; prevent thrombosis; and endotheliocyte there is protective effect; the blood vessel injury that can cause medmain, Kallidin I, antibacterial mycin, oxygen-derived free radicals keeps capillary permeability.Can increase oxygen content and oxygen saturation in the blood, activity, the microcirculation improvement of enzyme under the protection anaerobic condition promote neovascularity to generate to promote collateral circulation; thereby cerebral blood flow increasing amount; improve the blood supply in half blanking bar zone, alleviate the edema of neighboring area, reduce brain infarction area.
Use injection for treating 60 routine acute cerebral infarction patients of the present invention in this example, total effective rate is 93%, obvious effective rate is 70%, with matched group significant difference is arranged relatively, and the neurologic impairment integration reduces obviously after the treatment, whole blood viscosity, plasma viscosity obviously improve in the hemorheology, show that injection of the present invention can improve cerebral blood flow and blood viscosity, obviously alleviating the nervous function damage of cerebral infarction, and do not have obvious adverse reaction, is the active drug of treatment cerebral infarction.
Claims (8)
1, a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that described pharmaceutical composition is formed by Cerebrolysin Vial that extracts in the mammal cerebral tissue except that the people and troxerutin assembly, containing troxerutin in the pharmaceutical composition is the 1-1000 weight portion, and wherein the weight ratio of total nitrogen content is 70～90 in troxerutin and the Cerebrolysin Vial.
2, according to the described pharmaceutical composition of claim 1, the weight ratio that it is characterized in that total nitrogen content in troxerutin and the Cerebrolysin Vial is 80.
3, according to claim 1 or 2 described preparation of drug combination methods, it is characterized in that this preparation method comprises that the preparation of Cerebrolysin Vial and Cerebrolysin Vial and troxerutin are mixed in proportion, containing troxerutin in the pharmaceutical composition is the 1-1000 weight portion, wherein the weight ratio of total nitrogen content is 70～90 in troxerutin and the Cerebrolysin Vial, makes finished product preparation through post processing then.
4, preparation method according to claim 3, it is characterized in that, the preparation process of described Cerebrolysin Vial is: the animal brain of getting fresh and healthy, add the homogenate of 0.5-2.5 times of weight water for injection, be heated to 80-95 ℃, kept 15-30 minute, be cooled to hydrolysis temperature, be adjusted to the enzymolysis pH value, add the proteolytic enzyme of brain weight 0.1-1.5%, carry out primary enzymolysis or secondary enzymolysis, primary enzymolysis liquid or secondary enzymolysis liquid, are handled through centrifugal filtration after 8-24 hour 4-8 ℃ of placement, and filtrate is the ultrafilter membrane ultrafiltration of 6000-10000 with molecular cut off, ultrafiltrate is a Cerebrolysin Vial, and its total nitrogen content is 0.1～10mg/ml.
5, preparation method according to claim 4, it is characterized in that, described primary enzymolysis is behind the proteolytic enzyme that adds brain weight 0.1-1.5%, kept 2-20 hour at this proteolytic enzyme hydrolysis temperature, keep the enzymolysis pH value, be heated to 80-95 ℃ and kept 15-30 minute then, primary enzymolysis liquid; Described proteolytic enzyme is a trypsin, and hydrolysis temperature is 37-42 ℃, and the enzymolysis pH value is 7.8-8.2; Centrifugal filtration after the described primary enzymolysis is treated to: centrifugal back separation of supernatant, and with supernatant liquid filtering, the filtrate adjust pH is 3.5-4.5, be heated to 80-95 ℃, kept 15-30 minute, placed 8-24 hour at 4-8 ℃, centrifugal back separation of supernatant, with supernatant liquid filtering, the filtrate adjust pH is 6.5-7.5, is heated to 80-95 ℃, kept 15-30 minute, placed 8-24 hour at 4-8 ℃, centrifugal then, supernatant gets filtrate after filtration.
6, preparation method according to claim 4, it is characterized in that, described secondary enzymolysis process is for to be cooled to hydrolysis temperature with primary enzymolysis liquid, be adjusted to the enzymolysis pH value, the proteolytic enzyme that adds brain weight 0.1-1.5% enzymolysis 2-20 hour, keeps the enzymolysis pH value, be heated to 80-95 ℃ then and kept 15-30 minute, get secondary enzymolysis liquid; Described proteolytic enzyme is a pepsin, and it is 37-42 ℃ that enzymolysis is fit to temperature, and it is 2.5-3.2 that enzymolysis is fit to pH value; Centrifugal filtration after the described secondary enzymolysis is treated to: centrifugal back separation of supernatant, and with supernatant liquid filtering, the filtrate adjust pH is 8.0-10.0, be heated to 80-95 ℃, kept 15-30 minute, placed 8-24 hour at 4-8 ℃, centrifugal back separation of supernatant, with supernatant liquid filtering, the filtrate adjust pH is 6.5-7.5, is heated to 80-95 ℃, kept 15-30 minute, placed 8-24 hour at 4-8 ℃, centrifugal then, supernatant gets filtrate after filtration.
According to each described preparation method of claim 3-6, it is characterized in that 7, described centrifugal condition is 4000 rev/mins, centrifugation time is 15-30 minute.
According to each described preparation method of claim 3-6, it is characterized in that 8, the dosage form of described finished product preparation is tablet, capsule, granule, oral liquid, small-volume injection, bulk capacity injection or lyophilized injectable powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410070499XA CN1264522C (en) | 2003-08-07 | 2004-08-05 | Medicinal composition, its preparation method and its use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03153115 | 2003-08-07 | ||
| CN03153115.6 | 2003-08-07 | ||
| CNB200410070499XA CN1264522C (en) | 2003-08-07 | 2004-08-05 | Medicinal composition, its preparation method and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1589811A CN1589811A (en) | 2005-03-09 |
| CN1264522C true CN1264522C (en) | 2006-07-19 |
Family
ID=34621012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410070499XA Expired - Lifetime CN1264522C (en) | 2003-08-07 | 2004-08-05 | Medicinal composition, its preparation method and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1264522C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102718857B (en) * | 2012-07-09 | 2013-05-22 | 河北智同医药控股集团有限公司 | Denatured protein powder and brain protein hydrolyzate prepared from same |
| CN104511008B (en) * | 2013-09-26 | 2018-03-06 | 西藏易明西雅医药科技股份有限公司 | A kind of Cerebrolysin Vial preparation method |
| CN104511007B (en) * | 2013-09-26 | 2018-03-06 | 西藏易明西雅医药科技股份有限公司 | A kind of preparation method of Cerebrolysin Vial |
| CN104497102B (en) * | 2014-12-10 | 2017-08-04 | 内蒙古天奇生物科技有限公司 | A kind of pig brain polypeptide for preventing and treating the nervous system disease and preparation method thereof |
| CN113908174B (en) * | 2021-10-29 | 2022-06-24 | 北京四环制药有限公司 | Efficient and safe preparation method and application of cerebroprotein hydrolysate |
-
2004
- 2004-08-05 CN CNB200410070499XA patent/CN1264522C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1589811A (en) | 2005-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1354669A (en) | Pharmaceutical compositions of erythropoietin | |
| CN1644208A (en) | China fir extracts with lycopodine A and B composition and their preparing method | |
| CN1264522C (en) | Medicinal composition, its preparation method and its use | |
| CN1308033C (en) | Medicine for decreasing vagina acidity and treating vaginitis, use thereof | |
| CN119752690A (en) | Lactobacillus reuteri and metaplasia product capable of adjusting emotion and relieving mental stress and application thereof | |
| CN1771992A (en) | Brain extract and its prepn and use | |
| CN1258538A (en) | Health food made of silkworm for treating diabetes and hyperlipemia and its production process | |
| CN1883638A (en) | Compound medicine for treating depression and method for preparing same | |
| CN1915986A (en) | High purified tanshinone IIA sodium sulfonate, fabricating method, and preparation | |
| CN1813797A (en) | Medicinal composition, and its preparing method and use | |
| CN1634413A (en) | Bastard speedwell injection and preparation method thereof | |
| CN1879648A (en) | A multi-vitamin lyophilized formulation and preparation method thereof | |
| CN1522747A (en) | Medicament for treating coronary heart disease or coronary heart disease combined with cardiac insufficiency and preparation method thereof | |
| CN1686166A (en) | Medicinal composition for treating blood vessel kind disease, its preparation process and its use | |
| CN1562352A (en) | Technique for producing injection of freeze drying powder of A type botulinus toxin in use for treatment, and formula of protectant of freeze drying powder | |
| CN1947727A (en) | Anti-echidnotoxin blood serum and its preparing method | |
| US20230148308A1 (en) | Dual-enzyme composition for preventing, treating and/or alleviating veisalgia and symptoms associated therewith | |
| CN1147296C (en) | Preparation method of medicine for resisting ischemic cerebrum and brain trauma using taurine | |
| CN1634091A (en) | Injectio of gastrodine, its preparing process and usage | |
| CN101041060A (en) | Method for preparing encephalon glycoside and ignotin injection and the agent thereof | |
| CN1887906A (en) | Hypoglycemic polypeptide from silkworm and its prepn and use | |
| CN1887282A (en) | Medicine composition containing bailobalide | |
| CN1803182A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1830434A (en) | Preparation method of troxerutin injection | |
| CN1751691A (en) | Small volume intravenous injection of gastrodine and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: DOBORIPHY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: JAMES -ANDY PHARMACEUTICAL (TONGHUA) CO., LTD. Effective date: 20080822 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080822 Address after: No. 66, Xiangjiang Road, Meihekou, Jilin Patentee after: Aerbeila Medicine Holding (Tonghua) Co.,Ltd. Address before: Eastern section of North Ring Road, Meihekou, Jilin Patentee before: James -Andy Pharmaceutical (Tonghua) Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: DOPHI PHARMACEUTICAL(CHINA) CO., LTD. Free format text: FORMER NAME: DOBRAFI MEDICINE CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 135000 No. 66, Xiangjiang Road, Meihekou, Jilin Patentee after: DUOFEI PHARMACEUTICAL (CHINA)CO.,LTD. Address before: 135000 No. 66, Xiangjiang Road, Meihekou, Jilin Patentee before: Aerbeila Medicine Holding (Tonghua) Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: JILIN SIHUAN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: DUPROFIT PHARMACEUTICAL (CHINA) CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 135000 No. 66, Xiangjiang Road, Meihekou, Jilin Patentee after: Beijing Tianxinyuan Pharmaceutical Science and Technology Development Co.,Ltd. Address before: 135000 No. 66, Xiangjiang Road, Meihekou, Jilin Patentee before: DUOFEI PHARMACEUTICAL (CHINA)CO.,LTD. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Wang Jianhui Inventor before: Zhang Zhi |
|
| COR | Change of bibliographic data | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060719 |